ID   RPMI-8402
AC   CVCL_1667
SY   RPMI 8402; RPMI8402; Roswell Park Memorial Institute 8402; 8402
DR   BTO; BTO:0001880
DR   CLO; CLO_0008874
DR   CLO; CLO_0009857
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-1994
DR   BioSample; SAMN03471272
DR   BioSample; SAMN10988543
DR   cancercelllines; CVCL_1667
DR   Cell_Model_Passport; SIDM00403
DR   ChEMBL-Cells; CHEMBL3307964
DR   ChEMBL-Targets; CHEMBL612517
DR   Cosmic; 801732
DR   Cosmic; 909702
DR   Cosmic; 913427
DR   Cosmic; 932767
DR   Cosmic; 998726
DR   Cosmic; 999753
DR   Cosmic; 1012115
DR   Cosmic; 1037681
DR   Cosmic; 1115587
DR   Cosmic; 1151791
DR   Cosmic; 1175132
DR   Cosmic; 1191706
DR   Cosmic; 1224369
DR   Cosmic; 1281383
DR   Cosmic; 1330501
DR   Cosmic; 1524817
DR   Cosmic; 1641386
DR   Cosmic; 1664527
DR   Cosmic; 1760531
DR   Cosmic; 2458761
DR   Cosmic; 2462860
DR   Cosmic; 2602930
DR   Cosmic; 2733531
DR   Cosmic-CLP; 909702
DR   DepMap; ACH-000636
DR   DSMZ; ACC-290
DR   DSMZCellDive; ACC-290
DR   EGA; EGAS00001000978
DR   GDSC; 909702
DR   GEO; GSM887549
DR   GEO; GSM888632
DR   GEO; GSM1670390
DR   GEO; GSM5137742
DR   IARC_TP53; 2503
DR   LiGeA; CCLE_140
DR   LINCS_LDP; LCL-1022
DR   NCBI_Iran; C184
DR   PharmacoDB; RPMI8402_1328_2019
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1667
DR   PubChem_Cell_line; CVCL_1667
DR   Wikidata; Q54951273
RX   CelloPub=CLPUB00338;
RX   DOI=10.1007/978-1-4757-1647-4_11;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2255914;
RX   PubMed=2501659;
RX   PubMed=2985879;
RX   PubMed=3039492;
RX   PubMed=3159941;
RX   PubMed=3518877;
RX   PubMed=3874327;
RX   PubMed=4547172;
RX   PubMed=9933131;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=15472075;
RX   PubMed=16408098;
RX   PubMed=17170727;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=22675565;
RX   PubMed=26589293;
RX   PubMed=26870252;
RX   PubMed=27397505;
RX   PubMed=29496689;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=35354797;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Genetically heterogenous.
CC   Doubling time: ~48 hours (DSMZ=ACC-290).
CC   HLA typing: A*01:01,29:01; B*07:05,38:01; C*12:03,15:05 (PubMed=26589293).
CC   HLA typing: A*01:01:01,29:01:01; B*07:05:01,38:01:01; C*12:03:01,15:05:02 (DSMZCellDive=ACC-290).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 6641; LMO1 + HGNC; 12252; TRD; Name(s)=LMO1-TRD (PubMed=2501659; PubMed=29496689).
CC   Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (PubMed=2255914; PubMed=29496689).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Homozygous (PubMed=22675565; PubMed=26870252; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1583_Gln1584insProValGluLeuMetProProGlu (c.4750_4751insCCGTGGAGCTGATGCCGCCGGAGC); Zygosity=Heterozygous (PubMed=15472075).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Heterozygous (PubMed=22675565; PubMed=26870252; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=22675565; PubMed=26870252; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser121Ter (c.362C>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.88%; Native American=0%; East Asian, North=2.78%; East Asian, South=0%; South Asian=0%; European, North=60.56%; European, South=35.77% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-1994; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=29496689
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12 (ATCC; DSMZ)
ST   D13S317: 12 (Cosmic-CLP; PubMed=29496689)
ST   D16S539: 10,11
ST   D18S51: 16,20
ST   D19S433: 12,13,14 (PubMed=29496689)
ST   D19S433: 12,14 (DSMZ)
ST   D21S11: 30
ST   D2S1338: 19,23
ST   D3S1358: 14,16
ST   D5S818: 12,13
ST   D7S820: 8,13
ST   D8S1179: 11
ST   FGA: 23
ST   Penta D: 9,11
ST   Penta E: 7,14
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 14,20
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_B7RD ! RPMI-8382
OI   CVCL_B7RE ! RPMI-8392
OI   CVCL_WV43 ! RPMI-8432
SX   Female
AG   16Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 40
//
RX   CelloPub=CLPUB00338;
RA   Moore G.E., Woods L.K., Minowada J., Mitchen J.R.;
RT   "Establishment of leukemia cell line with T cell characteristics.";
RL   In Vitro 8:434-434(1973).
//
RX   DOI=10.1007/978-1-4757-1647-4_11;
RA   Moore G.E.;
RT   "Cell lines from humans with hematopoietic malignancies.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.299-331; Springer; New York (1975).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2255914; DOI=10.1126/science.2255914;
RA   Aplan P.D., Lombardi D.P., Ginsberg A.M., Cossman J., Bertness V.L.,
RA   Kirsch I.R.;
RT   "Disruption of the human SCL locus by 'illegitimate' V-(D)-J
RT   recombinase activity.";
RL   Science 250:1426-1429(1990).
//
RX   PubMed=2501659; DOI=10.1128/mcb.9.5.2124-2132.1989;
RA   McGuire E.A., Hockett R.D., Pollock K.M., Bartholdi M.F.,
RA   O'Brien S.J., Korsmeyer S.J.;
RT   "The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell
RT   line activates multiple transcripts, including Ttg-1, a gene encoding
RT   a potential zinc finger protein.";
RL   Mol. Cell. Biol. 9:2124-2132(1989).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3039492; DOI=10.1073/pnas.84.16.5565;
RA   Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y.,
RA   Okada K.;
RT   "Characterization of a mammalian mutant with a camptothecin-resistant
RT   DNA topoisomerase I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:5565-5569(1987).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=4547172; DOI=10.1093/jnci/53.3.655;
RA   Huang C.C., Hou Y., Woods L.K., Moore G.E., Minowada J.;
RT   "Cytogenetic study of human lymphoid T-cell lines derived from
RT   lymphocytic leukemia.";
RL   J. Natl. Cancer Inst. 53:655-660(1974).
//
RX   PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7;
RA   Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.;
RT   "Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines:
RT   suggestion for classification by immunophenotype and T-cell receptor
RT   studies.";
RL   Leuk. Res. 23:19-27(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22675565; DOI=10.1371/journal.pone.0038463;
RA   Atak Z.K., De Keersmaecker K., Gianfelici V., Geerdens E.,
RA   Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G.,
RA   Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P.,
RA   Cools J., Aerts S.;
RT   "High accuracy mutation detection in leukemia on a selected panel of
RT   cancer genes.";
RL   PLoS ONE 7:E38463-E38463(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26870252; DOI=10.3892/ol.2015.3959;
RA   Stoczynska-Fidelus E., Piaskowski S., Pawlowska R., Szybka M.,
RA   Peciak J., Hulas-Bigoszewska K., Winiecka-Klimek M., Rieske P.;
RT   "Genetic heterogeneity of RPMI-8402, a T-acute lymphoblastic leukemia
RT   cell line.";
RL   Oncol. Lett. 11:593-599(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29496689; DOI=10.21873/cgp.20068;
RA   Kjeldsen E., Nielsen C.J.F., Roy A., Tesauro C., Jakobsen A.-K.,
RA   Stougaard M., Knudsen B.R.;
RT   "Characterization of camptothecin-induced genomic changes in the
RT   camptothecin-resistant T-ALL-derived cell line CPT-K5.";
RL   Cancer Genomics Proteomics 15:91-114(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//